PACKAGE LEAFLET

Beaphar WORMclear® 230/20 mg Film-Coated tablets for cats

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
C&H Generics Ltd
c/o Michael McEvoy and Co
Seville House
New Dock Street
Galway
Ireland

Manufacturer responsible for batch release:
Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
Ireland

Distributor:
Beaphar UK Ltd, Rook Tree Farm, Withersfield Road, Great Wratting, Suffolk, CB9 7HD.

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Beaphar WORMclear® 230/20 mg Film-Coated Tablets for Cats
pyrantel embonate, praziquantel

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each film-coated tablet contains Pyrantel embonate 230 mg and Praziquantel 20 mg.
A white to off white round, biconvex coated tablet with a breakline on one side and plain on the other side.

4. INDICATION(S)

For the treatment of mixed infections caused by the following gastrointestinal roundworms and tapeworms:
Roundworms: *Toxocara cati, Toxascaris leonina.*
Tapeworms: *Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis*.

5. CONTRAINDICATIONS

Do not use simultaneously with products containing piperazine.
Do not use simultaneously with other deworming products without veterinary advice.
Do not use in kittens less than 6 weeks of age.
Do not use in animals with known hypersensitivity to the active substances or to any of the excipients.
Do not use during pregnancy.

6. ADVERSE REACTIONS

Mild and short-lived digestive tract disorders such as excessive salivation and/or vomiting and mild and short-lived disorders of the nervous system such as loss of balance may occur in very rare cases.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)

If you notice any side effects, even those not already listed in this package leaflet or if you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Cats.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Dosage
The recommended dose is: 20 mg/kg pyrantel (57.5 mg/kg pyrantel embonate) and 5 mg/kg praziquantel.
This is equivalent to 1 tablet per 4 kg body weight.
Administration and duration of treatment
Single oral administration. The tablet should be given directly to the cat, but if necessary can be disguised in food.

Body weight (kg)	Tablets
1.0 up to 2.0 kg	½
Greater than 2.0 up to 4.0 kg	1
Greater than 4.0 up to 6.0 kg	1½
Greater than 6.0 kg	2

In ascarid infestation, especially in kittens, complete elimination cannot be expected, so a risk of infection for humans can persist. Repeat treatments should, therefore, be carried out with a suitable roundworm product at 14 day intervals until 2-3 weeks after weaning.
If signs of disease persist or appear, consult a veterinary surgeon.

9. ADVICE ON CORRECT ADMINISTRATION

To ensure administration of a correct dose, body weight should be determined as accurately as possible

10. WITHDRAWAL PERIOD

N/A

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use after the expiry date stated on the blister and carton. The expiry date refers to the last day of that month.
Unused halved tablets should be discarded.
Do not remove tablets from the immediate packaging until required for use.

Keep blister in outer carton.

12. SPECIAL WARNING(S)

Special precautions for use in animals.
Do not use during pregnancy but may be used during lactation.
Not intended for use in cats less than 6 weeks of age or weighing less than 1 kg body weight.
If your cat receives other veterinary medicinal products, check with a veterinary surgeon or pharmacist before using this product.
Do not use simultaneously with any other deworming products.
Do not use in animals with an allergy to the active substances or any of the excipients.
Do not exceed the stated dose; in the event of an overdose seek immediate veterinary advice.
After doses higher than 5 times the recommended dose, signs of intolerance such as vomiting have been observed. Development of parasite resistance to anthelmintics of a certain class can occur after frequent and repeated use of an anthelmintic from that class.
Fleas serve as intermediate hosts for one common type of tapeworm – *Dipylidium caninum*. Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken.

User Warnings.
In case of accidental ingestion, seek medical advice and show the package leaflet or carton to the physician.
In the interests of good hygiene, persons administering the tablets directly to a cat or adding them to the cat's food should wash their hands afterwards.
For animal treatment only.
Other precautions
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority (e. g. experts or institutes of parasitology). If the cat has visited areas where Echinococcus species are prevalent, a veterinarian should be consulted.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

August 2020.

15. OTHER INFORMATION

2 tablets.

AVM-GSL

Vm 40162/4011

11790-B / LC10233